Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2025-03-27 Regulatory Filings
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
OSLO BØRS – TRADING RESUMPTION
Regulatory Filings Classification · 95% confidence The document text is extremely short (142 characters) and announces the resumption of trading following a previous announcement. This is a brief, time-sensitive market notification regarding trading status, not a comprehensive financial report, management change, or shareholder vote result. Given the options, this type of general, immediate regulatory/exchange announcement that doesn't fit specific financial reporting categories (like 10-K, ER, or DIV) is best classified under the general regulatory fallback category.
2025-03-27 English
Nykode Therapeutics – resignation of Chair of the Board, Board Members, Chief Executive Officer, Chief Scientific Officer and Chief Financial Officer
Board/Management Information Classification · 100% confidence The document explicitly announces the resignation of several key personnel: the Chair of the Board, Board Members, the Chief Executive Officer, the Chief Scientific Officer, and the Chief Financial Officer. This directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management. The document is a formal announcement of these departures.
2025-03-27 English
OSLO BØRS - TRADING SUSPENSION
Delisting Announcement Classification · 99% confidence The document text is extremely short (169 characters) and announces a 'TRADING SUSPENSION' in anticipation of a company announcement. This is a brief, immediate regulatory action or notice related to market activity, not a comprehensive financial report (like 10-K or IR) or a specific shareholder vote/director dealing report. Since it is a general regulatory notice concerning market operations that doesn't fit the specific categories like DIV, DIRS, or DLST (which is for delisting, not temporary suspension), the most appropriate fallback category is Regulatory Filings (RNS).
2025-03-27 English
Nykode Therapeutics Announces Preclinical Data Highlighting its Immune Tolerance Platform’s Ability to Modulate Multiple Key Immune Components in Autoimmune Disease
Regulatory Filings Classification · 90% confidence The document is titled "Company Announcement" and details the release of new preclinical data regarding the company's immune tolerance platform, presented at a scientific summit. It is a press release format announcing scientific progress, not a comprehensive annual report (10-K), an interim report (IR), or a formal regulatory filing like a DEF 14A or DVA. Since it is an announcement of scientific findings and platform progress, it most closely aligns with a general corporate update or investor-focused communication. Given the options, it is not a specific financial report, management change, or transaction notice. It is a general announcement of scientific progress, which often falls under Regulatory Filings (RNS) if no better fit exists, or potentially an Investor Presentation (IP) if it were the presentation itself. However, since it is a press release *about* data presented elsewhere, and it doesn't fit the specific categories like ER, AR, or CT, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for a non-standard corporate update, although it shares characteristics with an Investor Presentation (IP) announcement. Given the content is a news release about data, RNS is the safest general classification for corporate news releases that aren't earnings or management changes.
2025-02-27 English
Nykode Therapeutics Announces Preclinical Data Highlighting its Immune Tolerance Platform’s Ability to Modulate Multiple Key Immune Components in Autoimmune Disease
Regulatory Filings Classification · 91% confidence The document is a press release titled "Nykode Therapeutics Announces Preclinical Data Highlighting its Immune Tolerance Platform’s Ability to Modulate Multiple Key Immune Components in Autoimmune Disease." It details new scientific findings, presentation at a summit, and includes standard sections like 'About Nykode Therapeutics' and 'Forward-looking statements'. This format is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it is announcing scientific data and progress rather than summarizing quarterly financial performance (which would suggest ER or IR), and it is not a transcript (CT) or a formal regulatory filing like a 10-K, it best fits the category for initial announcements of results or progress. Given the focus on scientific data presentation, it is most closely aligned with an Earnings Release (ER) which often includes operational/pipeline updates, or potentially an Investor Presentation (IP) if it were the slides themselves. However, as a press release announcing data presented at a summit, it functions as an immediate public disclosure of operational/scientific progress, making 'Earnings Release' (ER) the most appropriate fit among the provided options for a significant, non-financial-statement-focused announcement, or potentially 'Regulatory Filings' (RNS) if it were a general update. Given the content is a scientific update announcement, and not a formal financial report, 'ER' is often used for such immediate operational news releases. If a more specific scientific update category existed, it would be preferred. Lacking that, and noting it's a formal announcement of progress, I will classify it as an Earnings Release (ER) as these often contain pipeline updates, or RNS as a general announcement. Since it is a specific announcement of data, and not a general regulatory filing, ER is slightly better than RNS, though it is not strictly an earnings report. Given the options, and the nature of biotech announcements, ER is often used for these types of press releases. However, since it is purely scientific data announcement and not tied to a financial period summary, 'Regulatory Filings' (RNS) serves as a strong fallback for significant, non-standard announcements. I will lean towards RNS as the most accurate general category for a scientific data press release that isn't a formal financial report or presentation.
2025-02-27 English
Nykode Therapeutics - Quarterly report Q4 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled '4TH QUARTER 2024 INTERIM REPORT' and contains comprehensive financial statements, including income statements, balance sheet data, and detailed management discussion and analysis (MDA) for the quarter and year ended December 31, 2024. It is a substantive financial report rather than a short announcement or certification, fitting the definition of an Interim/Quarterly Report. Q4 2024
2025-02-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.